282 related articles for article (PubMed ID: 33506203)
1. Clinical correlates for immune checkpoint therapy: significance for CNS malignancies.
Ratnam NM; Frederico SC; Gonzalez JA; Gilbert MR
Neurooncol Adv; 2021; 3(1):vdaa161. PubMed ID: 33506203
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
5. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors for the treatment of melanoma.
Sabbatino F; Liguori L; Pepe S; Ferrone S
Expert Opin Biol Ther; 2022 May; 22(5):563-576. PubMed ID: 35130816
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond.
Buder-Bakhaya K; Hassel JC
Front Immunol; 2018; 9():1474. PubMed ID: 30002656
[TBL] [Abstract][Full Text] [Related]
8. Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
Tamanna MT; Egbune C
Cancer Treat Res; 2023; 185():79-89. PubMed ID: 37306905
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.
Remon J; Passiglia F; Ahn MJ; Barlesi F; Forde PM; Garon EB; Gettinger S; Goldberg SB; Herbst RS; Horn L; Kubota K; Lu S; Mezquita L; Paz-Ares L; Popat S; Schalper KA; Skoulidis F; Reck M; Adjei AA; Scagliotti GV
J Thorac Oncol; 2020 Jun; 15(6):914-947. PubMed ID: 32179179
[TBL] [Abstract][Full Text] [Related]
10. Integrin signaling gene alterations and outcomes of cancer patients receiving immune checkpoint inhibitors.
Vlachostergios PJ
Am J Transl Res; 2021; 13(11):12386-12394. PubMed ID: 34956460
[TBL] [Abstract][Full Text] [Related]
11. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
Rizzo A; Mollica V; Massari F
Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
[TBL] [Abstract][Full Text] [Related]
12. Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors.
Mason NJ; Chester N; Xiong A; Rotolo A; Wu Y; Yoshimoto S; Glassman P; Gulendran G; Siegel DL
MAbs; 2021; 13(1):2004638. PubMed ID: 34856888
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMBĀ and PD-L1.
Lefler DS; Snook AE; Bashir B
Immunotherapy; 2022 Aug; 14(11):885-902. PubMed ID: 35694998
[TBL] [Abstract][Full Text] [Related]
14. Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.
Hotta K; Fujimoto N
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32098830
[TBL] [Abstract][Full Text] [Related]
15. Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy.
Lau SCM; Poletes C; Le LW; Mackay KM; Fares AF; Bradbury PA; Shepherd FA; Tsao MS; Leighl NB; Liu G; Shultz D; Sacher AG
Lung Cancer; 2021 Jun; 156():76-81. PubMed ID: 33932863
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers for response to immunotherapy in hepatobiliary malignancies.
Lin ZF; Qin LX; Chen JH
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):413-419. PubMed ID: 35973935
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.
Jessurun CAC; Vos JAM; Limpens J; Luiten RM
Front Oncol; 2017; 7():233. PubMed ID: 29034210
[TBL] [Abstract][Full Text] [Related]
18. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
[TBL] [Abstract][Full Text] [Related]
19. Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?
Lee SM; Lee S; Cho HW; Min KJ; Hong JH; Song JY; Lee JK; Lee NW
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674491
[TBL] [Abstract][Full Text] [Related]
20. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies.
Atkins MB; Ascierto PA; Feltquate D; Gulley JL; Johnson DB; Khushalani NI; Sosman J; Yap TA; Kluger H; Sullivan RJ; Tawbi H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]